文献速递乳腺癌

浸润性小叶乳腺癌患者的当前与未来诊断和治疗策略

Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer.
PubMed 文献 · Ann Oncol · 2022-05-21

本文综述浸润性小叶乳腺癌(ILC)的诊断、分子特征(按ESCAT指南)、早期与转移阶段治疗及ILC专属临床试验的最新数据。影像学上MRI和新型PET/CT可克服现有技术局限,病理上E-cadherin免疫组化有助于提高病理医师间一致性。多数ILC患者从(新)辅助化疗中获益似乎不如非特殊型(NST)患者,但高危亚组可能需要化疗;抗HER2治疗和CDK4/6抑制剂疗效未见差异。

要点

  • MRI和新型PET/CT技术可克服现有影像学诊断ILC的局限。
  • E-cadherin免疫组化有助于提高病理医师间诊断一致性。
  • 多数ILC患者从(新)辅助化疗中获益似乎不如NST患者,高危亚组可能仍需化疗。

核心结论

  • ILC是一种独特的恶性肿瘤,其病理和生物学特征导致其诊断、治疗反应、耐药和靶点与NST不同。

研究设计与样本

  • 综述,呈现ILC在诊断、按ESCAT指南的分子构成、早期和转移阶段治疗及ILC聚焦临床试验方面的最新数据。

主要发现

  • 影像学层面,基于磁共振成像和新型正电子发射断层扫描/计算机断层扫描的技术可克服当前用于诊断ILC的影像技术的局限。
  • 病理学层面,E-cadherin免疫组化可帮助提高病理医师间一致性。
  • 多数ILC患者从(新)辅助化疗中的获益似乎不如NST患者,尽管高危亚组患者可能需要化疗。
  • 辅助治疗中抗HER2治疗及转移阶段CDK4/6抑制剂的疗效未见差异。
  • 商业可及的预后基因表达检测对ILC患者的临床效用尚不明确。

关键数值与推荐

  • 体细胞HER2突变在ILC中更常见,尤其在转移灶中(ILC 15% vs NST 5%)。
  • 高肿瘤突变负荷(与免疫检查点抑制相关)在ILC转移灶中更常见(16%) than NST转移灶(5%)。
  • 胚系BRCA1和PALB2变异在ILC患者中较少见,而胚系CDH1变异在ILC患者中更常见。
  • 携带体细胞失活CDH1突变的肿瘤可能对ROS1抑制剂治疗敏感,该概念正在早期和转移性ILC中研究。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Invasive lobular breast cancer (ILC) is the second most common type of breast cancer after invasive breast cancer of no special type (NST), representing up to 15% of all breast cancers. DESIGN: Latest data on ILC are presented, focusing on diagnosis, molecular make-up according to the European Society for Medical Oncology Scale for Clinical Actionability of molecular Targets (ESCAT) guidelines, treatment in the early and metastatic setting and ILC-focused clinical trials. RESULTS: At the imaging level, magnetic resonance imaging-based and novel positron emission tomography/computed tomography-based techniques can overcome the limitations of currently used imaging techniques for diagnosing ILC. At the pathology level, E-cadherin immunohistochemistry could help improving inter-pathologist agreement. The majority of patients with ILC do not seem to benefit as much from (neo-)adjuvant chemotherapy as patients with NST, although chemotherapy might be required in a subset of high-risk patients. No differences in treatment efficacy are seen for anti-human epidermal growth factor receptor 2 (HER2) therapies in the adjuvant setting and cyclin-dependent kinases 4 and 6 inhibitors in the metastatic setting. The clinical utility of the commercially available prognostic gene expression-based tests is unclear for patients with ILC. Several ESCAT alterations differ in frequency between ILC and NST. Germline BRCA1 and PALB2 alterations are less frequent in patients with ILC, while germline CDH1 (gene coding for E-cadherin) alterations are more frequent in patients with ILC. Somatic HER2 mutations are more frequent in ILC, especially in metastases (15% ILC versus 5% NST). A high tumour mutational burden, relevant for immune checkpoint inhibition, is more frequent in ILC metastases (16%) than in NST metastases (5%). Tumours with somatic inactivating CDH1 mutations may be vulnerable for treatment with ROS1 inhibitors, a concept currently investigated in early and metastatic ILC. CONCLUSION: ILC is a unique malignancy based on its pathological and biological features leading to differences in diagnosis as well as in treatment response, resistance and targets as compared to NST.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Van Baelen K, Geukens T, Maetens M, et al. Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer. Ann Oncol. 2022. PMID: 35605746. doi:10.1016/j.annonc.2022.05.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。